{"id":175041,"date":"2026-09-27T19:35:00","date_gmt":"2026-09-27T19:35:00","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/175041\/"},"modified":"2026-09-27T19:35:00","modified_gmt":"2026-09-27T19:35:00","slug":"ozempic-maker-novo-nordisks-investors-are-nervously-looking-into-the-future","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/175041\/","title":{"rendered":"Ozempic Maker Novo Nordisk\u2019s Investors Are Nervously Looking Into the Future"},"content":{"rendered":"<p class=\"css-12m5bll evys1bk0\">For Novo Nordisk, the Danish drugmaker behind Ozempic and Wegovy, the release of its weight-loss pill has been a much-needed triumph.<\/p>\n<p class=\"css-12m5bll evys1bk0\">It was a scientific breakthrough to make an effective tablet form of Wegovy, a weekly injection. It was also a commercial success: More than 1.5 million people, mostly in the United States, have started taking the daily pill since it became available in January.<\/p>\n<p class=\"css-12m5bll evys1bk0\">But the company\u2019s investors have not been dazzled. They are nervously looking further into the future. The key U.S. patent on semaglutide, the active ingredient in Wegovy, will expire early in the next decade.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Just a few years ago, Novo Nordisk was the darling of the health care industry. It had pioneered a <a class=\"css-povzk\" href=\"https:\/\/www.nytimes.com\/2026\/06\/08\/well\/glp1-drugs-weight-loss.html\" title=\"\" rel=\"nofollow noopener\" target=\"_blank\">single drug<\/a> with benefits that went beyond weight loss to heart, liver and other cardiovascular diseases.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Today Novo\u2019s share price is languishing about 70 percent below its peak from mid-2024, when it was Europe\u2019s most valuable public company. Investor sentiment is still shaky even after the company said last month that sales and profit would not <a class=\"css-povzk\" href=\"https:\/\/www.nytimes.com\/2026\/02\/04\/business\/novo-nordisk-wegovy-sales-earnings.html\" title=\"\" rel=\"nofollow noopener\" target=\"_blank\">fall as much as expected this year<\/a>.<\/p>\n<p class=\"css-12m5bll evys1bk0\">As Mike Doustdar, Novo Nordisk\u2019s chief executive, sees it, investors are missing the big picture. They are too focused on the company\u2019s rivalry with the American drugmaker Eli Lilly. They are not appreciating the variety of drugs Novo has available and in development.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cWe have more assets than people are giving us credit for,\u201d Mr. Doustdar said in an interview with The New York Times. \u201cIn a world where people need more treatment medications, it\u2019s not a zero-sum game.\u201d<\/p>\n<p>Customers, Not Patients<\/p>\n<p class=\"css-12m5bll evys1bk0\">Mr. Doustdar\u2019s desire to bring a new energy to the company, and revive its fortunes, is evident in the intense way he talks about the company\u2019s naysayers. His voice is often loud, even assertive. \u201cWe haven\u2019t lost it,\u201d he said.<\/p>\n<p class=\"css-12m5bll evys1bk0\">He took over in August 2025 in uncomfortable circumstances. The previous chief executive had been forced out a few months earlier by the company\u2019s principal shareholder and board member, the Novo Nordisk Foundation. In October, the company\u2019s chair and all the independent board members quit.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The situation became more fraught after Lars Rebien Sorensen, the chair of the foundation\u2019s board, installed himself as chair of the company\u2019s board. The dual role of Mr. Sorensen, who is also a former chief executive of Novo, unnerved some shareholders, including Norway\u2019s oil fund.<\/p>\n<p class=\"css-12m5bll evys1bk0\">But drastic change was necessary. Novo began the modern era of weight-loss drugs, known collectively as GLP-1s, but had <a class=\"css-povzk\" href=\"https:\/\/www.nytimes.com\/2025\/08\/07\/business\/ozempic-wegovy-novo-nordisk-decline.html\" title=\"\" rel=\"nofollow noopener\" target=\"_blank\">lost much of its lead to competition<\/a> from Eli Lilly and cheaper compounding pharmacies. And there had been a steady drumbeat of bad news: profit warnings, <a class=\"css-povzk\" href=\"https:\/\/www.nytimes.com\/2025\/11\/06\/health\/obesity-drug-prices-trump.html\" title=\"\" rel=\"nofollow noopener\" target=\"_blank\">forced price cuts<\/a>, disappointing trials and slowing prescription growth.<\/p>\n<p class=\"css-12m5bll evys1bk0\">In a first, painful step, Novo laid off about 9,000 employees, the largest restructuring in Danish corporate history.<\/p>\n<p class=\"css-12m5bll evys1bk0\">One big shift in the past year has been rhetorical. Mr. Doustdar speaks frequently about serving customers, not just treating patients. He wants the company to cater to anyone who needs the drugs, without judgment about why. Being able to buy weight-loss drugs with a prescription, but without an in-person doctor\u2019s visit, can support people who suffer from shame and depression because of their weight, he said.<\/p>\n<p class=\"css-12m5bll evys1bk0\">That has raised the question \u2014 internally and externally \u2014 whether Novo is becoming a cosmetics company. This debate, Mr. Doustdar said, is a distraction.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cWe have science that works and is safe and efficacious, and there are customers that need it,\u201d he said. \u201cIt\u2019s irresponsible not to go in that direction.\u201d<\/p>\n<p>An American Mind-Set<\/p>\n<p class=\"css-12m5bll evys1bk0\">Novo Nordisk has sharpened its commercial instincts \u2014 and its elbows \u2014 as Mr. Doustdar seeks to prove the company\u2019s best days aren\u2019t in the past.<\/p>\n<p class=\"css-12m5bll evys1bk0\">It is rebranding Rybelsus, which in 2019 was the first semaglutide pill approved for Type 2 diabetes, to \u201cthe Ozempic pill,\u201d belatedly taking advantage of the brand recognition. The company is also increasingly litigious. It had taken legal action against more than 150 companies over various claims, and last month sued Eli Lilly over \u201cdeceptive advertising\u201d in the United States.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The company is starting to appear more American. Even with its 103-year Danish history, Novo makes more than half of its sales in the United States, where it employs 10,000 people. The number of Novo workers in Denmark shrank by 13 percent last year but grew in the United States by the same proportion.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Whether consciously or not, that shift is a reflection of Mr. Doustdar. He is the company\u2019s first non-Danish leader. He was born in Iran and is an Austrian national who grew up in the United States. Mr. Doustdar has been at Novo Nordisk for more than 30 years, but primarily in international operations, so he had never worked at headquarters in the Copenhagen suburbs.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Mr. Doustdar emphasized the company\u2019s American ties when he was negotiating last year with President Trump, who was threatening to impose tariffs on imported medicines. The company is plowing ahead with a $4 billion expansion in Clayton, N.C., next to a production facility it opened 30 years ago.<\/p>\n<p class=\"css-12m5bll evys1bk0\">For American consumers, Novo Nordisk makes the Wegovy pill from start to finish in North Carolina, across two locations in Clayton and Durham, which are about an hour\u2019s drive apart.<\/p>\n<p>Buying Time<\/p>\n<p class=\"css-12m5bll evys1bk0\">Are any of these changes enough to convince investors that Novo\u2019s future is not as grim as its share price suggests?<\/p>\n<p class=\"css-12m5bll evys1bk0\">Companies can reverse their ill fortunes. But the successes, like those of Microsoft and Best Buy, are few and far between.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cYou\u2019re more likely to get a Nokia than a Microsoft,\u201d said Randall Peterson, a professor of organizational behavior at London Business School, referring to the Finnish company that lost an early lead in the cellphone business.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Hassan Chowdhry, a portfolio manager at GMO Asset Management, said he had divested from Novo Nordisk this year. The trigger was the disappointing trial results of CagriSema, Novo\u2019s next-generation weight-loss drug, which is expected to be available early next year, subject to U.S. approval. In February, Novo failed to prove it was more efficacious at weight loss than an existing Eli Lilly drug it would compete with.<\/p>\n<p class=\"css-12m5bll evys1bk0\">While Mr. Chowdhry expects weight loss to be a $150 billion market with plenty of room for two big players, he said that Novo had a long way to go before it could release a really competitive product. For example, another drug, Zenagamtide, is likely years away from coming to market.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cThere doesn\u2019t seem to be any catalyst in the immediate term that might push the stock up in a major way,\u201d Mr. Chowdhry said.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Some analysts and Novo shareholders want the company to diversify, possibly through acquisitions. Nearly 95 percent of its sales came from diabetes and obesity medicines in the first half of 2026. Eli Lilly, by comparison, has growing investments in neuroscience and immunology.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Among those vocal investors is Markus Manns, a portfolio manager at Union Investment in Frankfurt, who owns shares in both companies. Novo Nordisk, he said, is \u201cstill lacking a vision for sustainable growth,\u201d though he is hopeful the company will detail one at an investor meeting this month.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The constant comparisons with Lilly frustrate Mr. Doustdar. For investors, the rivalry has become like an \u201cobsession,\u201d he said.<\/p>\n<p class=\"css-12m5bll evys1bk0\">But the comparisons with Lilly will be hard to shake, especially because the company is expected to seek U.S. approval for its next-generation drug, retatrutide, early next year.<\/p>\n<p class=\"css-12m5bll evys1bk0\">So what will change the sentiment about Novo Nordisk? \u201cTime,\u201d Mr. Doustdar said.<\/p>\n<p class=\"css-12m5bll evys1bk0\">CagriSema promises to be a test case. Though investors aren\u2019t enthusiastic about it, the drug will be available relatively soon.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cIt\u2019s a much better drug than right now investors are writing in their models,\u201d Mr. Doustdar said. \u201cBut like I said, I don\u2019t need to sell this to investors. I need to sell these to physicians who understand the biology better.\u201d<\/p>\n<p><a aria-label=\"Show Eshe Nelson's comment in comments panel\" class=\"css-8g8ihq css-1ixbp0l\" href=\"#\"><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/cropped-22a6d9b9595d5437708ffd9a8d798fea1ce97f63ddda980566495f99696b579ad5eceb66.png\" class=\"css-12b39xn\" alt=\"\"\/><\/p>\n<p>Eshe Nelson<\/p>\n<p>Reporter covering Europe\u2019s economy<\/p>\n<p class=\"css-10iylmx\" style=\"-webkit-line-clamp:unset\">One of the big changes for Novo Nordisk in the past year was that it cut U.S. prices for Ozempic and Wegovy after negotiations with the Trump administration. Those price cuts, along with slowing prescription growth, meant the company forecast a decline in revenue. Now it&#8217;s hoping that lower prices translates into more volume sales, including through Medicare. The company also hopes patients will be less easily lured by compounding pharmacies if their own drugs are cheaper too.<\/p>\n<p><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"For Novo Nordisk, the Danish drugmaker behind Ozempic and Wegovy, the release of its weight-loss pill has been&hellip;\n","protected":false},"author":2,"featured_media":175042,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[26,75862,80455,80454,31954,42228,272,1273,31953,80456,12334],"class_list":["post-175041","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-denmark","tag-doustdar","tag-drugs-pharmaceuticals","tag-durham-nc","tag-glp-1-ras-drug","tag-mike","tag-novo-nordisk","tag-novo-nordisk-a-s","tag-ozempic-drug","tag-vis-photo","tag-weight"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117344687297345821","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/175041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=175041"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/175041\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/175042"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=175041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=175041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=175041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}